1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase-Reference-Cited by-同舟云学术

1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase

Published:2019-01 Issue: Volume:162 Page:612-630
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Lai Mei-Jung,Ojha Ritu,Lin Mei-Hsiang,Liu Yi-Min,Lee Hsueh-Yun^ORCID,Lin Tony Eight,Hsu Kai-Cheng,Chang Chi-Yen,Chen Mei-Chuan,Nepali Kunal,Chang Jang-Yang,Liou Jing-Ping^ORCID

Funder

Ministry of Science and Technology, Taiwan

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference73 articles.

1. Therapeutic protein kinase inhibitors;Grant;Cell. Mol. Life Sci.,2009

2. Blocking blood flow to solid tumors by destabilizing tubulin: an approach to targeting tumor growth;Pérez-Pérez;J. Med. Chem.,2016

3. Novel combretastatin-2-aminoimidazole analogues as potent tubulin assembly inhibitors: exploration of unique pharmacophoric impact of bridging skeleton and aryl moiety;Chaudhary;J. Med. Chem.,2016

4. Synthesis and biochemical evaluation of 3-phenoxy-1,4-diarylazetidin-2-ones as tubulin-targeting antitumor agents;Greene;J. Med. Chem.,2016

5. Potent antitumor activities and structure basis of the chiral β-lactam bridged analogue of combretastatin A-4 binding to tubulin;Zhou;J. Med. Chem.,2016

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of class I HDAC modulators: Inhibitors and degraders;European Journal of Medicinal Chemistry;2024-10

2. The Potential Strategies for Overcoming Multidrug Resistance and Reducing Side Effects of Monomer Tubulin Inhibitors for Cancer Therapy;Current Medicinal Chemistry;2024-04

3. Design, Synthesis and Mechanistic Study of New Dual Targeting HDAC/Tubulin Inhibitors;Future Medicinal Chemistry;2024-03-22

4. Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator;Medical Oncology;2024-03-05

5. Discovery of novel coumarin-based derivatives as inhibitors of tubulin polymerization targeting the colchicine binding site with potent anti-gastric cancer activities;European Journal of Medicinal Chemistry;2024-02